A
To evaluate the potential side effects of the drug
You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Advertisement
A first-in-class, claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate may be a new treatment option for patients with advanced gastric/gastroesophageal junction (GEJ) cancers, according to data presented by Xu et al during the ASCO Plenary Series: November 2023 Session (Abstract 434420).